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ABSTRACT
Introduction: In November 2013, Scotland piloted a program in Grampian for the treatment of
Urinary Tract Infections (UTIs) in community pharmacies, increasing health access for patients
and reducing general practitioner workload. This program became known as ‘Pharmacy First’ and
was later implemented nationwide in November 2017. This paper seeks to understand utilization
of the Pharmacy First program across Scotland by patients and potential barriers to access.

Methods: Using data from the Prescribing Information System collected by the National Health
Service of Scotland from July 2013 to April 2019, orders for uncomplicated UTIs were gathered
by examining all nitrofurantoin and trimethoprim prescriptions dosed according to the National
Institute for Health and Care Excellence (NICE) guidelines (allowing up to a maximum 7 day
supply), including women 16-65 years of age (those who would qualify for Pharmacy First).
Prescribing rates for UTIs by community pharmacists were compared to all prescribers, and rates
were broken down by age, location by regional health board, and socioeconomic quintile based on
2019 data from quarter one.

Results: In Q1 2019, 12,628 UTI prescriptions were prescribed by community pharmacists in
Scotland for women 16-65 years of age, comprising 19% of all UTI prescriptions in that group. In
two of the first three health boards to have implemented the service, the numbers were even higher
at 29%. Community pharmacists prescribed 23% of UTI prescriptions for women in the highest
socioeconomic quintile and 16% of UTI prescriptions for women in the lowest socioeconomic
quintile. Women 51-65 years of age received 31% fewer prescriptions from community
pharmacists than women 16-50 years of age.
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Discussion: Data suggests Pharmacy First has seen significant growth, particularly since its
implementation nationwide in 2017. As earlier implementers have higher rates of Pharmacy First
use, there is still room for growth nationally. Differences between socioeconomic status and age
groups suggest that there may be barriers to access or issues in patient acceptability and preference.

Conclusion: These findings could be used to reinforce that the role of the community pharmacist
can be enhanced in the diagnosis and treatment of uncomplicated UTIs with the potential for
protocol extensions to other common conditions. There may be some differences in patient access
and acceptability of such services, and this warrants further study.
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INTRODUCTION
Following a study in 2010 for the treatment of uncomplicated urinary tract infections
(UTIs) conducted across 20 pharmacies in Scotland,1 Grampian (one of 14 health boards in
Scotland) approved the first regional program in the nation for the treatment of urinary tract
infections within community pharmacies in 2013.2 By 2017, all health boards within Scotland had
approved the program, which became known as Pharmacy First and has since expanded to include
other services such as treatment for impetigo. This service was intended to reduce workload for
general practitioners and to increase access to care for patients, who can be seen immediately by a
pharmacist that can prescribe an appropriate treatment.3
In order to better understand the legal framework surrounding Pharmacy First, it’s
important to know that non-physician health professionals in Scotland can supply medications
through policies called Patient Group Directions (PGDs), which must be approved by both a
physician and a pharmacist practicing in Scotland. PGDs are required to define the condition that
is intended to be treated, the type of health professional allowed to prescribe under the PGD,
inclusion and exclusion criteria for patients to be treated under the PGD, the medications allowed
to be supplied, key counseling points, and follow-up actions, if needed.4 Each of Scotland’s 14
health boards have approved a separate PGD, which are similar in terms of inclusion and exclusion
criteria. However, two health boards (Greater Glasgow and Clyde and Tayside) differ in that they
allow trimethoprim or nitrofurantoin as antibiotic treatment options rather than just
trimethoprim.5,6
To meet the inclusion criteria to be treated through Pharmacy First, potential patients must
be females 16 to 65 years of age presenting with either both dysuria and polyuria or three or more
of any of the following symptoms: dysuria, polyuria, urgency, hematuria, or suprapubic
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tenderness. Exclusion criteria includes male sex, age less than 16 or over 65, pregnancy, vaginal
itching or discharge, symptoms suggestive of upper urinary tract infection (fever, nausea,
vomiting, diarrhea, chills, loin pain or tenderness, or systemically unwell), a prior UTI in the past
28 days, 2 or more UTIs in the last 6 months, 3 or more UTIs in the last 12 months, use of a
catheter, moderate to severe renal impairment, sensitivity to the antibiotics allowed under the PGD,
or use of medications with significant interaction with antibiotics allowed under the PGD.5,6
The aforementioned criteria are designed to prevent patients who might require a higher
level of care or a more thorough diagnostic work-up from being inappropriately treated under the
PGD. For example, patients with a complicated UTI (by definition all males) or a recurrent UTI
may require urine cultures to help guide antibiotic selection, which cannot be performed within
pharmacies, and patients with vaginal pruritus or discharge may not have a UTI. Of note, there is
some variability between health boards in terms of exclusion criteria, and since the PGD must be
renewed every three years, there have been some changes made in the originally implemented
PGDs, such as the Grampian health board’s decision to remove diabetes as an exclusion criteria in
2018.6
After a patient has been screened, the pharmacist can then decide if referral to a general
practitioner is required or if treatment with trimethoprim 200 mg three times daily for three days
(or an equivalent three day course of nitrofurantoin if the health board PGD allows it) is
appropriate. A urine dipstick test can be considered as part of the screening criteria but is not
required and not routinely recommended because it adds little diagnostic value and results in an
unnecessary increase in healthcare costs.6
One study was published in 2010 regarding the use of community pharmacies as centers
for the treatment of urinary tract infections.1 Little data have been published regarding the use of
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Pharmacy First since it was approved regionally in the Grampian health board in 2013,2 and even
less has been published regarding its use nationwide since approval in 2017.3 To the best of my
knowledge, this study is the first study evaluating how successful Pharmacy First has been, if
Pharmacy First is continuing to expand, whether certain patient populations are benefiting more
or less from the services, and how this program can affect the future of public health and
community pharmacy practice in Scotland. I will use data from the national Prescribing
Information System (PIS) to track the number of prescriptions for uncomplicated UTIs in Scotland
prescribed by pharmacists via Pharmacy First versus other providers in 2013 – 2019. I hypothesize
that the reliance on the Pharmacy First initiative as a means of managing uncomplicated UTIs has
increased over time.
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LITERATURE REVIEW
Although the concept of being assessed and prescribed a medication by a community
pharmacist may sound like a novel concept, a routine responsibility of community pharmacists
includes conducting assessments of patients when they present to the pharmacy with a complaint
and, if the condition can be treated with an over the counter medication without a referral,
recommending an appropriate therapy. Scotland established a program in 2006 called the Minor
Ailment Scheme so that pharmacists could assess patients and prescribe over the counter
medications. This enabled qualified patients to receive their medications at no cost, and
pharmacists to receive reimbursement for their services. 7 Through exposure to these programs,
many patients in Scotland already have experience with being assessed and prescribed a
medication by a pharmacist well before Pharmacy First was implemented in Grampian in 2013.2
In the United States, similar changes have been expanding the services provided by
community pharmacies. In 2004, New Mexico authorized the first statewide protocol in the United
States granting community pharmacists prescriptive authority and allowing pharmacists within the
state to prescribe medications for smoking cessation.8 By 2009, all states have authorized protocols
permitting community pharmacies to offer and administer vaccines.9 As of 2019, nine states have
implemented protocols allowing pharmacists to prescribe birth control,8 and some states have even
approved protocols allowing community pharmacists to provide a wider array of services including
testing and treatment for urinary tract infections, influenza, streptococcal pharyngitis, and
substance use disorder.10
The goal of these expanded community pharmacy services both in the United States and in
Scotland is to provide greater access to medical care for patients and to reduce burden on primary
care. In the United States, an estimated shortage of 14,500 primary care physicians was reported

Borchardt 11
in 2017, and that number is expected to grow to somewhere between 21,000 and 55,200 by 2030.11
In Scotland, there has been a similar shortage of primary care services, which the government has
begun to address with plans to not only hire more physicians but also to expand the role of allied
health providers including physical therapists and pharmacists.12
In general, pharmacists are considered one of the most easily accessible healthcare
providers. The vast majority of pharmacies offer hours beyond typical business hours, and most
are also open on weekends. Additionally, 91% of Americans live within five miles of a pharmacy,
making pharmacists much more accessible from a geographical access-to-care perspective as
well.13 Finally, pharmacists already have training and experience in diagnosing and treating minor
ailments, so it is logical that community pharmacists might play a role in public health and
increased access to medical care.13
Although less is known about Pharmacy First, other widespread community pharmacybased services have been reported to increase access to care and reduce costs. In the United States,
one study found that nearly one third of patients utilizing community pharmacies for
immunizations went outside typical business hours.14 Therefore, enhanced community pharmacybased services can play a vital role in increasing access to primary care. A systematic review of
pharmacy-based immunization services found that pharmacy-based vaccinations significantly
reduced costs compared to physician clinics, demonstrating that pharmacy-based services are not
only more accessible but also more cost effective. However, the same report noted reduced access
to pharmacy-based immunization services in medically underserved communities.15 Therefore, an
important step in evaluating Pharmacy First data will include evaluating the programs use among
patients residing in more rural areas and also examining usage rates by socioeconomic status.
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Overall, pharmacists in both Scotland and the United States are beginning to see an
increased role in addressing public health concerns, particularly in providing infectious disease
prevention, testing, and treatment services. Data from the United States indicate that pharmacists
can also play an important role in increasing access to medical care in underserved areas as most
pharmacies offer extended hours of service compared to medical clinics, are conveniently located,
and can see patients without an appointment. As both countries consider further expansion of
pharmacy services, it will be important to understand the services in terms of usage and disparities
in access, which this research will address using Pharmacy First in Scotland as an example.
Additional factors that will not be addressed in this paper but warrant further research include
patient and provider acceptability and cost.
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METHODS
Study Purpose
Data were collected every yearly quarter on the total number of prescriptions for UTIs
written for first line antibiotics (i.e., trimethoprim and nitrofurantoin) in Scotland between the
initiation of Pharmacy First and the first quarter of 2019 using data from the Prescribing
Information System of Scotland. Before data extraction, inclusion and exclusion criteria used by
Pharmacy First such as patient age were applied so that only UTI prescriptions dispensed to
patients potentially eligible for Pharmacy First were measured. The number of UTI prescriptions
prescribed overall as well as specifically through Pharmacy First was obtained to calculate the
prevalence of Pharmacy First utilization each quarter. Additionally, data from the most recent
quarter (quarter one of 2019) will be used to describe the utilization of Pharmacy First by age,
health board, and socioeconomic status.
Study Population
Data extracted from the Prescribing Information System included patient demographics
(e.g., age, gender, and health board), prescribers, and medications (e.g., name, strength, and
quantity). This database does not include a diagnosis associated with a particular prescription or a
patient’s medical history. However, the diagnosis of an uncomplicated UTI could be inferred as
nitrofurantoin and trimethoprim (the only two first-line therapies for uncomplicated UTIs) are used
almost exclusively for UTIs, and the quantity being dispensed corresponds to whether those
antibiotics are being used as treatment for uncomplicated UTIs, treatment for complicated UTIs,
or prophylaxis for patients with recurrent UTIs (which is further discussed below).
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Study Design
I conducted a descriptive analysis using data from quarter one of 2019 (last quarter of
follow-up) and an interrupted time series analysis to assess the changes in the proportion of UTI
prescriptions prescribed through Pharmacy First relative to the total number of UTI prescriptions
between the quarter three of 2014 and quarter one of 2019. In order to differentiate prescriptions
initiated from Pharmacy First for UTIs versus other sources, prescriptions classified under the form
types “Urgent Supply of Medicines” and “Minor Ailment Scheme” within the Prescribing
Information System were assumed to have been initiated through Pharmacy First as those form
types are used exclusively by community pharmacists. Of note, the initial Pharmacy First pilot
program started in quarter four of 2013. However, Pharmacy First prescriptions were not submitted
using the standard community pharmacy prescription form types until quarter three of 2014, so
data before that point will not be included in this study.
For the descriptive analysis, we used a bivariate analysis to compare prescribing patterns
by age, health board, and socioeconomic status. The proportion of UTI prescriptions potentially
eligible for Pharmacy First that were prescribed through the program compared to the number of
potentially eligible prescriptions dispensed overall will be broken down by patient age in five-year
age bands, health board where the prescriptions were dispensed, and patient socioeconomic status
as reflected by their Scottish Index of Multiple Deprivation (SIMD) quintile. A SIMD quintile of
one reflects the lowest socioeconomic status, and a SIMD quintile of five reflects the highest
socioeconomic status.
Inclusion Criteria
Prescriptions for trimethoprim 100 mg tablets and nitrofurantoin 50 mg and 100 mg
capsules between the third quarter of 2014 and the first quarter of 2019 were included. These
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antibiotics are the only first line therapies recommended for patients with uncomplicated UTIs per
National Institute for Health and Care Excellence (NICE) guidelines, which are medical guidelines
followed by prescribers practicing in Scotland and the rest of the United Kingdom.
Exclusion Criteria
Prescriptions dispensed for patients who were male or for patients aged less than 16 years
or greater than 65 years were excluded. However, other exclusion criteria such as vaginal discharge
and history of diabetes could not be assessed as the Prescribing Information System does not store
patient medical histories or diagnoses.
Furthermore, trimethoprim and nitrofurantoin are both used primarily for treatment of
urinary tract infections and are the only first line therapies for this diagnosis. However, the drugs
can also be used for prevention of recurrent infections, and trimethoprim may also be used for
complicated urinary tract infections (neither of which are indications for community pharmacists
to dispense those antibiotics under Pharmacy First). In order to exclude prescriptions written for
those purposes, prescriptions written for a quantity of antibiotics corresponding to a supply greater
than seven days were excluded since complicated UTIs should be treated with trimethoprim for at
least two weeks and prescriptions written for UTI prophylaxis are generally written for quantities
of at least a one-month supply.16 A quantity of antibiotic corresponding to a seven-day supply was
14 for trimethoprim 100 mg tablets (dosed twice daily), 28 for nitrofurantoin 50 mg capsules
(dosed four times daily), and 14 for nitrofurantoin 100 mg capsules (dosed twice daily). Although
National Institute for Health and Care Excellence (NICE) guidelines do not recommend
trimethoprim and nitrofurantoin therapies be used for greater than three days in patients with
uncomplicated UTIs,
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prescribers sometimes choose a longer duration than what is

recommended, and it is not uncommon for prescribers to treat an uncomplicated UTI up to seven
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days, which is why a seven day supply was used as the maximum supply for a prescription to be
considered a treatment dose for an uncomplicated UTI.
Statistical Analysis
The percentages of all prescriptions for uncomplicated UTIs that were dispensed through
Pharmacy First each quarter were modeled using a segmented regression to detect whether there
were any changes in trend and level before and after the national launch of the program in quarter
four of 2017.18 Because the level change was not statistically significant, the final model was used
to test whether there has been any significant change in level in the percentage of prescriptions
through Pharmacy First after the national launch. The model was estimated using Prais-Winston
method to account for the first order autoregressive structure in the time series data.19 Stata SE v16
was used for statistical analysis.
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RESULTS
Pharmacy First Utilization by Calendar Year and Quarter
Between quarter three of 2014 and quarter one of 2019, the proportion of prescriptions
dispensed through Pharmacy First increased from less than 0.1% to 18.7%. Using a time series
analysis, the rate of growth in the proportion of prescriptions dispensed through Pharmacy First
before quarter four of 2017 (when Pharmacy First was implemented nationwide) was 0.26% each
quarter (95% confidence interval [CI], 0.11% - 0.40%). After quarter four of 2017, the rate of
growth of in the proportion of prescriptions dispensed through Pharmacy First increased ten-fold
to 2.66% per quarter (95% CI, 2.26% - 3.07%).
Figure 1: Pharmacy First Utilization by Calendar Year and Quarter

Percent of UTI Prescriptions from
Pharmacy First

Pharmacy First Use by Calendar Year and Quarter
20%
16%
12%
8%
4%
0%

Calendar Year and Quarter

Borchardt 18
Table 1: Pharmacy First Utilization by Calendar Year and Quarter

Calendar Year
and Quarter

Number of UTI
Antibiotic Prescriptions
from Pharmacy First

Total Number of
UTI Antibiotic
Prescriptions

Percent of UTI
Prescriptions Dispensed
through Pharmacy First

2014 Q3
2014 Q4
2015 Q1
2015 Q2
2015 Q3
2015 Q4
2016 Q1
2016 Q2
2016 Q3
2016 Q4
2017 Q1
2017 Q2
2017 Q3
2017 Q4
2018 Q1
2018 Q2
2018 Q3
2018 Q4
2019 Q1

7
11
19
46
117
186
332
658
855
1089
1246
1573
1883
2685
5733
7804
11323
12511
12628

68395
69307
63451
61295
67504
69037
64660
62187
68390
68006
65333
62150
68317
66826
63787
62213
71132
71186
67380

0.0%
0.0%
0.0%
0.1%
0.2%
0.3%
0.5%
1.1%
1.3%
1.6%
1.9%
2.5%
2.8%
4.0%
9.0%
12.5%
15.9%
17.6%
18.7%
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Pharmacy First Utilization by Health Board in Quarter One of 2019
As noted in Table 2 below, four health boards including Grampian, Forth Valley,
Lanarkshire, and Ayrshire and Arran had 13% to 59% higher Pharmacy First utilization rates than
the national average (all comparisons p < 0.05). Alternatively, seven health boards had
significantly lower Pharmacy First utilization for UTIs than the national average. One health board
(Western Isles) had no prescriptions dispensed through Pharmacy First during quarter one of 2019.

Figure 2: Pharmacy First Utilization by Health Board in Quarter One of 2019
Percent of UTI Prescriptions from Pharmacy
First

Pharmacy First Use by Health Board
35%
30%

25%
20%
15%
10%

5%
0%

Health Board
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Table 2: Pharmacy First Utilization by Health Board in Quarter One of 2019
Health Board
Ayrshire and Arran
Borders
Dumfries and
Galloway
Fife
Forth Valley
Grampian
Greater Glasgow
and Clyde
Highland
Lanarkshire
Lothian
Orkney
Shetland
Tayside
Western Isles
Overall Average

Percent of UTI
Prescriptions Dispensed
through Pharmacy First

Prevalence of Pharmacy
First Use Relative to
Nationwide Average

95%
Confidence
Interval

21.1%
17.3%

1.13
0.92

1.06,1.19
0.81,1.05

9.6%

0.51

0.44,0.59

16.2%
28.9%
29.4%

0.87
1.54
1.59

0.80,0.93
1.46,1.63
1.50,1.64

17.5%

0.93

0.90,0.97

12.7%
23.2%
15.4%
18.7%
15.4%
9.4%
0%
18.7%

0.60
1.24
0.82
1.00
0.71
0.50
-

0.55,0.66
1.19,1.29
0.78,0.86
0.75,1.33
0.53,0.96
0.46,0.55
-
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Pharmacy First Utilization by Age in Quarter One of 2019
Another difference in prevalence of Pharmacy First utilization can be seen among patients
in different age groups. When comparing patients 16 to 50 years of age to patients 51 to 65 years
of age, the latter group was 30% less likely to seek care through Pharmacy First (95% CI, 28% 32%).
Figure 3: Pharmacy First Utilization by Age in Quarter One of 2019

Pharmacy First Use by Age
Percent of UTI Prescriptions from
Pharmacy First

25%
20%
15%

10%
5%
0%
16-20

21-25

26-30

31-35

36-40

41-45

46-50

51-55

56-60

61-65

Age in Years

Table 3: Pharmacy First Utilization by Age in Quarter One of 2019
Patient Age

Percent of UTI
Prescriptions Dispensed
through Pharmacy First

Prevalence of Pharmacy
First Use Relative to
Overall Average

95%
Confidence
Interval

16-20
21-25
26-30
31-35
36-40
41-45
46-50
51-55
56-60
61-65
Overall Average

20.8%
23.1%
21.2%
20.1%
21.1%
21.0%
19.5%
17.4%
15.3%
11.2%
18.7%

1.11
1.23
1.13
1.08
1.12
1.12
1.04
0.93
0.81
0.60
N/A

1.05,1.17
1.18,1.29
1.08,1.19
1.02,1.13
1.07,1.18
1.06,1.19
0.99,1.09
0.88,0.97
0.77,0.86
0.56,0.64
N/A
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Pharmacy First Utilization by Socioeconomic Quintile in Quarter One of 2019
Pharmacy First use appears to be linearly increasing in higher SIMD groups. Pharmacy
First was more frequently used by people of higher socioeconomic statuses as indicated by higher
use among SIMD quintile five patients and lowest use among SIMD quintile one patients.
Compared to people in SIMD quintile five, people in SIMD quintile one were 31% less likely to
use Pharmacy First (95% CI, 28% to 34%)
Figure 4: Pharmacy First Utilization by Socioeconomic Quintile in Quarter One of 2019

Percent of UTI Prescriptions
from Pharmacy First

Pharmacy First Use by Socioeconomic Quintile
25%
20%
15%
10%
5%
0%
1

2

3

4

5

SIMD Quintile

Table 4: Pharmacy First Utilization by Socioeconomic Quintile in Quarter One of 2019
SIMD
Quintile
1
2
3
4
5
Overall
Average

Percent of UTI
Prescriptions Dispensed
through Pharmacy First

Prevalence of Pharmacy
First Use Relative to
Overall Average

95% Confidence
Interval

15.7%
17.9%
18.7%
20.3%
22.8%

0.79
0.94
1.00
1.11
1.27

0.76,0.83
0.91,0.98
0.96,1.04
1.06,1.15
1.22,1.32

18.7%

N/A

N/A
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DISCUSSION
Since the implementation of Pharmacy First as a pilot program in a single health
board (Grampian) in 2013, the percentage of women utilizing pharmacies for UTI management
has grown significantly, particularly since 2017 when Pharmacy First was implemented
nationwide. As of the most recent 12 months of data, over 44,000 prescriptions for antibiotics were
prescribed by community pharmacists for UTI treatment through Pharmacy First, accounting for
nearly 19% of UTI prescriptions in Scotland in the first quarter of 2019. Additionally, these
numbers are continuing to grow each quarter, and as more community pharmacists begin to offer
UTI treatment services and as more women become familiar with the process of using Pharmacy
First, these number can be expected to increase.
One difference in Pharmacy First utilization can be seen on the basis of age with women
51 to 65 years of age being 30% less likely to use Pharmacy First. A possible explanation is that
younger women may already be familiar with the process of using similar pharmacy services such
as the Minor Ailment Scheme, through which patients can receive some over the counter and
prescription medications such as emergency contraception. Additionally, younger women may feel
more comfortable discussing symptoms related to UTIs outside a general practitioner office. In the
future, more women may be expected to utilize Pharmacy First as younger patients who are more
familiar with pharmacy services continue to age and patients overall become more aware of how
to use Pharmacy First for UTI treatment. Alternatively, older women may be more likely to meet
exclusion criteria for UTI treatment for Pharmacy First such as taking medications with significant
drug interactions to the antibiotics authorized for use under Pharmacy First.
Additionally, there also appeared to be a disparity among patients using Pharmacy First
based on socioeconomic status (as measured by SIMD quintiles). Notably, people in the lowest
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socioeconomic quintile were 31% less likely to use Pharmacy First for UTI treatment. One factor
contributing to differences in utilization based on socioeconomic status could be that rural health
boards including the Western Isles were more likely to have implemented Pharmacy First later,
and as a result, fewer patients in lower socioeconomic areas (who are more likely to live in rural
areas) have access to community pharmacists who are offering UTI screening and treatment
services through Pharmacy First. Given more time as rural areas continue to further implement
Pharmacy First, the differences in Pharmacy First utilization by socioeconomic status may
decrease. Although, some rural areas lack pharmacies and instead have a general practitioner who
provides both prescribing and dispensing services. Therefore, patients in these rural areas do not
have access to a pharmacy in order to receive services through Pharmacy First.
Another possible factor contributing to differences in Pharmacy First utilization based on
socioeconomic status could be that women in the lower socioeconomic status quintiles are more
likely to meet exclusion criteria. Exclusion criteria such as having diabetes (which is more
prevalent among underserved populations) may result in fewer women in lower socioeconomic
status groups even being able to qualify for Pharmacy First. For some patients, this may result in
delays to care, especially if these women feel they cannot afford to miss work, and unfortunately,
these patients with diabetes will likely receive the same care through their general practitioners as
they would through Pharmacy First. Grampian’s health board has already decided to remove
diabetes as an exclusion criterion, but many rural health boards continue to use diabetes to exclude
those patients.6 Therefore, it is important to critically think about the disparities in access to care
for underserved populations caused by specific inclusion and exclusion criteria for Pharmacy First
programs. In the future, policy makers and practitioners should ensure that inclusion and exclusion
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criteria are not overly restrictive (particularly for the underserved) and carefully weigh the benefit
versus risk of those criteria to patients.
Data from this program indicate that pharmacy services for the management of acute
conditions such as UTIs are acceptable by a significant and growing portion of the population in
Scotland, and these results may promote the further expansion of Pharmacy First to other
conditions. Additionally, these results may be encouraging as other countries (including the United
States) continue to pilot and implement similar programs. In the United States, chain and
independent pharmacies alike are seeing the implementation of similar services including
substance use programs and influenza screening in some pharmacies. Considering it took Scotland
less than ten years to pilot UTI treatment programs in community pharmacies to see a nearly 20%
nationwide utilization of pharmacies for UTI treatments, it may be reasonable to believe the United
Kingdom as a whole as well as other countries could see the practice of pharmacy shift over the
next ten years as more pharmacies implement similar services. These changes could play an
essential public health role by improving access to care for patients and alleviating some of the
burden of medical provider shortages through community pharmacists.
Limitations and Future Directions
One limitation of this data is a lack of clinical outcomes. Although this data provided a
better understanding of how many people are using Pharmacy First compared to those continuing
to see their general practitioner, it will be important to know whether or not these patients were
successfully treated by following these patients after they receive their prescriptions. Additionally,
it will also be important to estimate the cost or savings to the health system by implementing
Pharmacy First. Therefore, research is needed to estimate costs in resources and time of pharmacy
staff to offer UTI screening and to compare them to those of primary care or urgent care services
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that these patients may be using instead. Before expanding the scope of Pharmacy First to other
common conditions, it would also be beneficial and important to understand from a patient
perspective how people felt after using Pharmacy First, whether it is a service they would
recommend or use again, and why people who did not use Pharmacy First chose to receive care
elsewhere. By conducting this research on patient satisfaction, it may also give insights into why
patients may choose to receive care elsewhere. Finally, while exclusion and inclusion criteria such
as age could be applied to the data in the Prescribing Information System to filter out prescriptions
for patients who may not qualify for Pharmacy First, other criteria such as renal impairment could
not. Therefore, this data may be overestimating the number of prescriptions potentially eligible for
Pharmacy First that were prescribed by general practitioners leading to an underestimate in the
percentage of potentially eligible prescriptions dispensed through Pharmacy First.
CONCLUSION
Overall, these results demonstrate the successful implementation of a community pharmacy
program for the treatment of UTIs across Scotland. These results also indicate further growth of
the program over the coming months and years. Moreover, these results may support the expansion
of Pharmacy First to other services and to areas outside of Scotland. Further research will be
needed to determine what extent exclusion criteria, patient perceptions, and other factors play in
determining the cause for disparities. Additionally, more information is needed to determine the
cost versus savings to the health system with regards to community pharmacists providing these
types of service.
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